ClinicalTrials.gg
CompletedNCT03739125Updated Aug 25, 2021

Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes

A Phase 3 interventional study of CKD-501 0.5mg and Placebo in Type2 Diabetes, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-08-25.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. lobeglitazone · Diabetes Mellitus, Type 2.

Enrollment
4th of 23
226 · median 41
Started
2017
the only one that year
Phase 3
5 of 23
none open now
Registered
13th of 23
by date
Lead sponsor
20 of 23
Chong Kun Dang Pharmaceutical

Among the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 3, and was the 13th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Where they have run

About lobeglitazone

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to prove that the group treated with CKD-501 in combination added that the reduction of glycated hemoglobin superior to placebo treated group added in combination.

Read the detailed description

The aim of this phase III study was to evaluate the efficacy and safety of additional combined CKD-501 administration for 24 weeks in patients with type 2 diabetes who were not adequately controlled for blood glucose by the combination of D150 and D745 10mg .

Furthermore, the extension study for additional 28 weeks is designed to confirm long term safety of CKD-501 as an oral hypoglycemic agent.

03

Conditions studied

  • Type2 Diabetes
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 19 years and 75 years old(male or female)
  • Type Ⅱ diabetes mellitus
  • The patient who has been taking oral hypoglycemic agent at least 8weeks with 7 to 10% at screening test
  • between 21kg/㎡ and 40kg/㎡
  • C-peptide level is over 1.0 ng/ml
  • Agreement with written
  • HbA1c 7 to 10% after Run-in period

Exclusion criteria

Exclusion Criteria:

  • Type I diabetes or secondary diabetes
  • Continuous or non continuous treatment(over 7 days) insulin within 3 months prior to screening
  • Treatment with TZD within 3months or patient who have experience such as reaction, serious adverse event or no effect by treatment with TZD, SGLT2, BU
  • Chronic(continuous over 7 days) oral or non oral treatment within 1 month prior to screening
  • Treatment with anti-obesity drugs within 3months
  • Past history: lactic acidosis or metformin
  • Acute or chronic metabolic acidosis including diabetic ketoacidosis
  • History of proliferative diabetic retinopathy
  • Severe infection, severe injury patients, patients of pre and post operation
  • Patients with urinary tract infection including urinary tract sepsis and pyelonephritis
  • Malnutrition, weakness, starvation, hyposthenia, pituitary insufficiency or adrenal insufficiency
  • History of malignant tumor within 5years
  • Drug abuse or history of alcoholism
  • Severe pulmonary dysfunction, severe GI disorder
  • History of myocardial infarction, heart failure, cerebral infarction, cerebral hemorrhage or unstable angina within 6 months
  • Fasting Plasma Glucose level is over 270 mg/dl
  • Triglyceride level is 500 mg/dl and over
  • Significant abnormal liver dysfunction
  • Anemia
  • Abnormality of thyroid function(out of significant normal TSH range )
  • is less than 60ml/min/1.73m\^2
  • Pregnant women or nursing mothers
  • Fertile women who not practice with appropriate methods
  • Participated in other trial within 4 weeks
  • Participating in other trial at present
  • In investigator's judgment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    CKD-501 0.5mg

    CKD-501 0.5mg

    Drug: CKD-501 0.5mg

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745

    Also known as: Lobeglitazone

  • DrugPlacebo

    orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745

06

What researchers measure

Primary outcomes

  1. Change from baseline in Glycosylated Hemoglobin (HbA1c)

    Time frame: Baseline, 24 weeks

Secondary outcomes

  1. Change from baseline in Glycosylated Hemoglobin (HbA1c)

    Time frame: Baseline, 52 weeks

  2. Change from baseline in Fasting plasma glucose

    Time frame: Baseline, 24 weeks, 52weeks

  3. Change from baseline in HOMA-IR(Homeostasis Model Assessment of Insulin Resistance)

    Time frame: Baseline, 24 weeks, 52weeks

  4. Change from baseline in HOMA-β(Homeostasis Model Assessment of β-cell function)

    Time frame: Baseline, 24 weeks, 52weeks

  5. Change from baseline in QUICKI(Quantitative Insulin Check Index)

    Time frame: Baseline, 24 weeks, 52weeks

  6. HbA1c target achievement rate at 24, 52weeks(HbA1c < 6.5%, 7%)

    Time frame: Baseline, 24 weeks, 52weeks

  7. Change from baseline in Total Cholesterol

    Time frame: Baseline, 24 weeks, 52weeks

  8. Change from baseline in Triglycerides

    Time frame: Baseline, 24 weeks, 52weeks

  9. Change from baseline in LDL-Cholesterol

    Time frame: Baseline, 24 weeks, 52weeks

  10. Change from baseline in HDL-Cholesterol

    Time frame: Baseline, 24 weeks, 52weeks

  11. Change from baseline in non-HDL-Cholesterol

    Time frame: Baseline, 24 weeks, 52weeks

  12. Change from baseline in Small Dense LDL-Cholesterol

    Time frame: Baseline, 24 weeks, 52weeks

  13. Change from baseline in FFA(Free Fatty Acid)

    Time frame: Baseline, 24 weeks, 52weeks

  14. Change from baseline in Apo-AⅠ

    Time frame: Baseline, 24 weeks, 52weeks

  15. Change from baseline in Apo-B

    Time frame: Baseline, 24 weeks, 52weeks

  16. Change from baseline in Apo-CⅢ

    Time frame: Baseline, 24 weeks, 52weeks

  17. Evaluate safety of CKD-501 from number of participants with adverse events

    Time frame: Baseline, 24 weeks, 52weeks

07

Study locations

1 site
  • Severance Hospital, Yonsei University Health System
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in May 2020, 30 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 30 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2018
First posted
Nov 13, 2018
StartActual
Nov 7, 2017
Primary completionActual
May 25, 2020
CompletionActual
Dec 2, 2020
Last update
Aug 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03739125
Responsible party
Sponsor
First posted
Nov 13, 2018
Start date
Nov 7, 2017
Primary completion
May 25, 2020
Completion
Dec 2, 2020
Last update
Aug 25, 2021

Study contacts

BongSoo Cha, Ph.D
study chair · Severance Hospital, Yonsei University Health System

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lobeglitazone

Start the discussion